PMID- 33819725
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1873-3727 (Electronic)
IS  - 0001-8686 (Linking)
VI  - 291
DP  - 2021 May
TI  - Preclinical developments of natural-occurring halloysite clay nanotubes in cancer 
      therapeutics.
PG  - 102406
LID - S0001-8686(21)00047-6 [pii]
LID - 10.1016/j.cis.2021.102406 [doi]
AB  - The natural world holds useful resources that can be exploited to design 
      effective therapeutic approaches. Ready-to-use tubular nanoclays, such as 
      halloysite clay nanotubes (HNTs), are widely available, cost-effective, and 
      sustainable submicron crystalline materials that have been showing great 
      potential towards chronic multifactorial and malignant diseases, standing out as 
      a promising anticancer nanotherapeutic strategy. Currently, several preclinical 
      studies have reported the application of HNTs in cancer research, diagnosis, 
      monitoring, and therapeutics. This groundbreaking review highlights the 
      preclinical knowledge hitherto collected concerning the application of HNTs 
      towards cancer therapy. Despite their reproducibility issues, HNTs were used as 
      nanoarchitectonic platforms for the delivery of conventional chemotherapeutic, 
      natural-occurring, biopharmaceutical, and phototherapeutic anticancer agents in a 
      wide range of in vitro and in vivo solid cancer models. Overall, in different 
      types of cancer mice models, the intratumoral and intravenous administration of 
      HNTs-based nanoplatforms induced tumor growth inhibition without causing 
      significant toxic effects. Such evidence raises a relevant question: does the 
      therapeutic benefit of the parenteral administration of HNTs in cancer outweigh 
      their potential toxicological risk? To answer this question further long-term 
      absorption-distribution-metabolism-excretion studies in healthy and cancer animal 
      models need to be performed. In cancer therapeutics, HNTs are envisaged as 
      promising platforms for cancer multi-agent therapy, enabling the combination of 
      different therapeutic modalities. Furthermore, HNTs might constitute suitable 
      nanotheranostic platforms. Nevertheless, to confirm the potential and safety of 
      the application of HNTs as nanodelivery systems for cancer therapy, it is 
      necessary to perform in-depth in vivo pharmacokinetics and pharmacodynamic 
      studies to further the translation to clinical trials.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Pereira, Irina
AU  - Pereira I
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
      Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal; LAQV, REQUIMTE, 
      Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
      Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal; LAQV, REQUIMTE, 
      Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de 
      Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
FAU - Saleh, Mahdi
AU  - Saleh M
AD  - Institute for Micromanufacturing, Louisiana Tech University, P.O. Box 10137, 
      Ruston 71272, Louisiana, USA.
FAU - Nunes, Claudia
AU  - Nunes C
AD  - LAQV, REQUIMTE, Department of Chemical Sciences, Faculty of Pharmacy, University 
      of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
FAU - Reis, Salette
AU  - Reis S
AD  - LAQV, REQUIMTE, Department of Chemical Sciences, Faculty of Pharmacy, University 
      of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
FAU - Veiga, Francisco
AU  - Veiga F
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
      Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal; LAQV, REQUIMTE, 
      Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
      Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal.
FAU - Paiva-Santos, Ana Claudia
AU  - Paiva-Santos AC
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
      Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal; LAQV, REQUIMTE, 
      Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
      Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal. Electronic address: 
      acsantos@ff.uc.pt.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210329
PL  - Netherlands
TA  - Adv Colloid Interface Sci
JT  - Advances in colloid and interface science
JID - 8706645
RN  - T1FAD4SS2M (Clay)
SB  - IM
MH  - Animals
MH  - Clay
MH  - Mice
MH  - *Nanotubes
MH  - *Neoplasms/drug therapy
MH  - Reproducibility of Results
OTO - NOTNLM
OT  - Biocompatibility
OT  - Biopharmaceutical
OT  - Cancer therapeutics
OT  - Chemotherapeutic agent
OT  - Halloysite
OT  - Photosensitizer
COIS- Declaration of Competing Interest None.
EDAT- 2021/04/06 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/04/05 20:14
PHST- 2021/01/19 00:00 [received]
PHST- 2021/03/24 00:00 [revised]
PHST- 2021/03/25 00:00 [accepted]
PHST- 2021/04/06 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2021/04/05 20:14 [entrez]
AID - S0001-8686(21)00047-6 [pii]
AID - 10.1016/j.cis.2021.102406 [doi]
PST - ppublish
SO  - Adv Colloid Interface Sci. 2021 May;291:102406. doi: 10.1016/j.cis.2021.102406. 
      Epub 2021 Mar 29.